16 results on '"Whitehouse JM"'
Search Results
2. Cytotoxic drugs for non-neoplastic disease.
- Author
-
Whitehouse JM
- Subjects
- Antineoplastic Agents adverse effects, Arthritis, Rheumatoid drug therapy, Bone Marrow Diseases chemically induced, Humans, Neoplasms chemically induced, Psoriasis drug therapy, Antineoplastic Agents therapeutic use
- Published
- 1983
- Full Text
- View/download PDF
3. Treating ovarian cancer.
- Author
-
Sweetenham JW, Mead GM, Whitehouse JM, and Williams CJ
- Subjects
- Carboplatin, Female, Humans, Antineoplastic Agents therapeutic use, Cisplatin therapeutic use, Organoplatinum Compounds therapeutic use, Ovarian Neoplasms drug therapy
- Published
- 1986
- Full Text
- View/download PDF
4. Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type.
- Author
-
Lister TA, Cullen MH, Beard ME, Brearley RL, Whitehouse JM, Wrigley PF, Stansfeld AG, Sutcliffe SB, Malpas JS, and Crowther D
- Subjects
- Adult, Aged, Antineoplastic Agents therapeutic use, Chlorambucil therapeutic use, Cyclophosphamide therapeutic use, Drug Therapy, Combination, Female, Humans, Lymphoma mortality, Lymphoma pathology, Male, Middle Aged, Neoplasm Staging, Prednisolone therapeutic use, Remission, Spontaneous, Vincristine therapeutic use, Antineoplastic Agents administration & dosage, Lymphoma drug therapy
- Abstract
Sixty-six untreated patients with advanced non-Hodgkin's lymphoma of favourable histological type were allocated alternately to initial treatment with cyclophosphamide, vincristine, and prednisolone or with chlorambucil. The complete remission rate was higher in the group receiving combination chemotherapy, but the overall response rate was the same for both groups. The mean duration of complete remission was the same as that of good partial remission, and was the same for both treatments. The duration of remission was influenced by histological type and extent of disease at presentation, but not age. Those who responded to the initial treatment (whether with complete or with good partial remission) survived significantly longer than did non-responders. It is concluded that neither treatment is satisfactory and that new treatment programmes are needed for patients with a favourable prognosis, especially young patients with extensive disease.
- Published
- 1978
- Full Text
- View/download PDF
5. Combination chemotherapy for acute lymphoblastic leukaemia in adults.
- Author
-
Lister TA, Whitehouse JM, Beard ME, Brearley RL, Wrigley PF, Oliver RT, Freeman JE, Woodruff RK, Malpas JS, Paxton AM, and Crowther D
- Subjects
- Adolescent, Adult, Aged, Asparaginase adverse effects, Asparaginase therapeutic use, Central Nervous System Diseases radiotherapy, Doxorubicin therapeutic use, Drug Therapy, Combination, Female, Humans, Male, Methotrexate therapeutic use, Middle Aged, Prednisolone therapeutic use, Remission, Spontaneous, Vincristine therapeutic use, Antineoplastic Agents therapeutic use, Leukemia, Lymphoid drug therapy
- Abstract
Fifty-one adults with acute lymphoblastic leukaemia were entered into a trial of intense initial chemotherapy and early "prophylaxis" of the central nervous system (CNS). Initial treatment with OPAL (Oncovin (vincristine), prednisolone, adriamycin (doxorubicin), and L-asparaginase (colaspase)) followed by craniospinal or cranial irradiation and intrathecal methotrexate produced remission in 36 patients (71%). Seventeen of these patients relapsed three to 18 months after the start of remission; the remainder had been in remission for 12 to 52 months by the end of the study. The predicted median duration of complete remission was 18.5 months. None of the four patients who initially had clinical evidence of CNS disease, three of whom also had leukaemic cells identical to those found in Burkitt's lymphoma, achieved remission. Those patients who initially had hepatomegaly or splenomegaly had a shorter remission than those without. The predicted median survival was 27 months in those who achieved complete remission, one month in those who did not, and 21 months overall. The addition of colaspase and doxorubicin to vincristine and prednisolone and the use of early CNS treatment clearly improved the remission rate among adults with acute lymphoblastic leukaemia, though the presence and length of remission was affected by the extent of disease at presentation. Burkitt-like leukaemia, which had a poor prognosis, is probably a separate disease and may benefit from a different therapeutic approach.
- Published
- 1978
- Full Text
- View/download PDF
6. Clinical aspects of Hodgkin's disease.
- Author
-
Mead GM and Whitehouse JM
- Subjects
- Adult, Aged, Combined Modality Therapy, Female, Hodgkin Disease pathology, Humans, Male, Middle Aged, Neoplasm Staging, Hodgkin Disease therapy
- Published
- 1988
- Full Text
- View/download PDF
7. Modern management of non-Hodgkin's lymphoma.
- Author
-
Mead GM and Whitehouse JM
- Subjects
- Humans, Lymphoma immunology, Lymphoma pathology, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Lymphoma therapy
- Published
- 1986
- Full Text
- View/download PDF
8. Intensive investigation in management of Hodgkin's disease.
- Author
-
Sutcliffe SB, Wrigley PF, Smyth JF, Webb JA, Tucker AK, Beard ME, Irving M, Stansfeld AG, Malpas JS, Crowther D, and Whitehouse JM
- Subjects
- Hodgkin Disease pathology, Humans, Laparotomy, Liver Neoplasms pathology, Lymphography, Spleen pathology, Splenectomy, Splenomegaly pathology, Hodgkin Disease diagnosis
- Abstract
Ninety-eight patients with clinically localised Hodgkin's disease underwent laparotomy and splenectomy to determine the extent of microscopic spread. In 68 patients the procedure was carried out for untreated disease apparently confined above the diaphragm. Abdominal disease cannot be confidently excluded on the basis of non-invasive investigation at presentation. Clinical assessment of splenic disease was unreliable unless gross splenomegaly was present. Pedal lymphography was accurate in assessing para-aortic and iliac disease but of no value in assessing other intra-abdominal lymph node involvement, including that of the mesenteric lymph node. Trephine bone marrow biopsy findings were normal in all patients before surgery, and only one patient was found to have diseased bone marrow by Stryker-saw biopsy at operation. Liver disease was identified at operation in nine patients, some of whom were asymptomatic with clinically undetectable splenic and nodal disease. Detailed clinical staging failed to detect disease in one-third of patients who underwent laparotomy. These studies show that if radiotherapy is to remain the treatment of choice for disease truly localised to lymph nodes a detailed staging procedure, including laparotomy and splenectomy, remains essential. The value of this potentially curative treatment is considerably diminished in the patient who has been inadequately staged.
- Published
- 1976
- Full Text
- View/download PDF
9. Chemotherapy of solid tumours: trials and tribulations.
- Author
-
Mead GM and Whitehouse JM
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Combined Modality Therapy, Female, Humans, Male, Neoplasms radiotherapy, Prognosis, Antineoplastic Agents therapeutic use, Neoplasms drug therapy
- Published
- 1984
- Full Text
- View/download PDF
10. Cis-platinum: a new anticancer agent.
- Author
-
Williams CJ and Whitehouse JM
- Subjects
- Animals, Cisplatin administration & dosage, Cisplatin adverse effects, Dogs, Drug Administration Schedule, Drug Hypersensitivity, Female, Half-Life, Hearing Disorders chemically induced, Humans, Kidney Diseases chemically induced, Magnesium blood, Male, Nausea chemically induced, Ovarian Neoplasms drug therapy, Testicular Neoplasms drug therapy, Urinary Bladder Neoplasms drug therapy, Cisplatin therapeutic use, Neoplasms drug therapy
- Published
- 1979
- Full Text
- View/download PDF
11. MVPP chemotherapy regimen for advanced Hodgkin's disease.
- Author
-
Sutcliffe SB, Wrigley PF, Peto J, Lister TA, Stansfeld AG, Whitehouse JM, Crowther D, and Malpas JS
- Subjects
- Adolescent, Adult, Age Factors, Aged, Child, Drug Therapy, Combination adverse effects, Female, Humans, Male, Mechlorethamine therapeutic use, Middle Aged, Prednisolone therapeutic use, Procarbazine therapeutic use, Prognosis, Remission, Spontaneous, Vinblastine therapeutic use, Antineoplastic Agents therapeutic use, Hodgkin Disease drug therapy
- Abstract
During January 1968 to December 1972, 133 patients with advanced Hodgkin's disease (HD) were admitted to hospital for combination chemotherapy with mustine, vinblastine, procarbazine, and prednisolone (MVPP regimen). Remission rates were 76% among 49 untreated patients and 90% among 42 patients who had relapsed after radiotherapy. The corresponding five-year survival rates were 65% and 86% respectively. Provided the observed yearly mortality (6%) remains unchanged 75% of patients who had previously received no treatment or irradiation and achieved remission are expected to continue in first remission after five years. Forty-two patients had received prior chemotherapy. They had lower remission and five-year survival rates (40% and 33% respectively), and fewer than half of those achieving remission were still in first remission after five years. There were several reasons for the poor prognosis in this group, including advanced-stage disease (stage IVB), age over 40, and achievement of remission.Chemotherapy was administered on an outpatient basis. Haematological toxicity and immediate drug-related side effects were similar to those of other regimens but there was no appreciable neurotoxicity. Most deaths were due to either HD itself or complications of advanced disease. Five malignancies other than HD occurred in patients who had received both single-agent chemotherapy and radiotherapy before MVPP chemotherapy. Two patients developed osteonecrosis of the femoral heads.Combination chemotherapy has a profound effect on the prognosis of advanced HD. The MVPP regimen yields results comparable to those of other regimens but with perhaps less toxicity.
- Published
- 1978
- Full Text
- View/download PDF
12. Risk of leukaemia associated with cancer chemotherapy.
- Author
-
Whitehouse JM
- Subjects
- Female, Humans, Leukemia, Radiation-Induced, Risk, Antineoplastic Agents adverse effects, Leukemia chemically induced
- Published
- 1985
- Full Text
- View/download PDF
13. Best documented practice.
- Author
-
Whitehouse JM
- Subjects
- Clinical Protocols, Female, Humans, Neoplasms therapy, Medical Audit methods, Therapeutics standards
- Published
- 1989
- Full Text
- View/download PDF
14. Smooth muscle antibody in malignant disease.
- Author
-
Whitehouse JM and Holborow EJ
- Subjects
- Adenocarcinoma immunology, Adolescent, Adult, Aged, Animals, Antigens, Neoplasm, Biliary Tract immunology, Breast Neoplasms immunology, Bronchial Neoplasms immunology, Carcinoma immunology, Female, Fluorescent Antibody Technique, Humans, Immunoglobulin G analysis, Immunoglobulin M analysis, Melanoma immunology, Middle Aged, Neuroblastoma immunology, Ovarian Neoplasms immunology, Rats, Autoantibodies analysis, Muscle, Smooth immunology, Neoplasms immunology
- Abstract
Smooth muscle antibody at titres of 1/10 or more was found in 54 (67.5%) out of 80 patients with malignant disease and in 9 (20%) out of 46 controls. The incidence of S.M. antibody ranged from 18/30 (60%) in malignant melanoma to 7/8 (83%) in carcinoma of the ovary. The presence of this antibody is possibly related to changes in the malignant cell membrane.A new antibody directed at an antigen presumed to be located in bile canaliculi among other sites is described.
- Published
- 1971
- Full Text
- View/download PDF
15. Adriamycin in the treatment of acute leukaemia.
- Author
-
Whitehouse JM, Crowther D, Bateman CJ, Beard ME, and Malpas JS
- Subjects
- Acute Disease, Adolescent, Adult, Aged, Antibiotics, Antineoplastic administration & dosage, Antibiotics, Antineoplastic adverse effects, Child, Child, Preschool, Cytarabine administration & dosage, Daunorubicin therapeutic use, Drug Resistance, Female, Humans, Leukemia, Lymphoid drug therapy, Leukemia, Myeloid, Acute drug therapy, Lymphoma, Non-Hodgkin drug therapy, Male, Middle Aged, Remission, Spontaneous, Antibiotics, Antineoplastic therapeutic use, Leukemia drug therapy
- Abstract
In a preliminary study a new antitumour antibiotic, adriamycin, was found to be capable of inducing complete remission in 6 out of 17 patients with acute lymphoblastic leukaemia and in one out of four with lymphoblastic lymphosarcoma despite the fact that these patients had either failed to respond or had relapsed after chemotherapy with agents recognized to be potentially successful in each condition. In five cases of acute lymphoblastic leukaemia adriamycin was used in combination with cytosine arabinoside-three achieved complete remission and two good partial remissions. This combination seems to merit further study in patients who have relapsed on the more conventional chemotherapeutic regimens in acute lymphoblastic leukaemia.In 13 patients with acute myelogenous leukaemia previously treated with daunorubicin and cytosine arabinoside no remissions were obtained with the dose range used.
- Published
- 1972
- Full Text
- View/download PDF
16. Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukaemia.
- Author
-
Crowther D, Bateman CJ, Vartan CP, Whitehouse JM, Malpas JS, Fairley GH, and Scott RB
- Subjects
- Adolescent, Adult, Aged, Asparaginase administration & dosage, Asparaginase adverse effects, Blood Cell Count, Clinical Trials as Topic, Cytarabine administration & dosage, Daunorubicin administration & dosage, Edema chemically induced, Female, Humans, Male, Middle Aged, Nausea chemically induced, Serum Albumin analysis, Vomiting chemically induced, Asparaginase therapeutic use, Cytarabine therapeutic use, Daunorubicin therapeutic use, Leukemia, Myeloid, Acute drug therapy
- Abstract
Cytosine arabinoside and daunorubicin used in an intensive intermittent regimen have been shown to be an effective combination for the induction of complete remissions in 14 out of 23 adult patients with acute myelogenous leukaemia. This gives an overall complete remission rate of 60%. A further patient had a good partial remission. The addition of L-asparaginase to the regimen has not increased the incidence of remission and there were more side effects in the L-asparaginasetreated group. Of the 10 patients treated with L-asparaginase in addition to cytosine arabinoside and daunorubicin, five achieved a complete remission. Of the 13 patients treated with cytosine arabinoside and daunorubicin without L-asparaginase, nine achieved a complete remission and one a good partial remission.
- Published
- 1970
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.